CLPBY (Coloplast AS) Net Change in Cash: $59 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPBY Coloplast AS CLPBY
77 GF Score
Price $6.70
GF Value $13.05
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Net Change in Cash?

Coloplast AS CLPBY -1.47% 77 Net Change in Cash is $59 Mil as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Coloplast AS's Net Change in Cash for the three months ended in Mar. 2026 was $-9 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2026 was $59 Mil.

Coloplast AS Net Change in Cash Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Net Change in Cash Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.30 -9.18 76.42 -13.10 32.55

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.65 4.33 36.33 27.91 -9.44
CLPBY
77GF Score
Coloplast AS CLPBY
Net Change in Cash is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Net Change in Cash Calculation

Coloplast AS's Net Change in Cash for the fiscal year that ended in Sep. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1044.976+-196.729+-815.694+0
=33

Coloplast AS's Net Change in Cash for the quarter that ended in Mar. 2026

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=226.749+-94.659+-144.464+2.939
=-9

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $59 Mil mean?
Coloplast AS (CLPBY) has a Net Change in Cash of $59 Mil as of Mar. 2026. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Coloplast AS and its competitors.
Is Coloplast AS's Net Change in Cash too high?
Coloplast AS's current Net Change in Cash is $59 Mil. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Net Change in Cash compare to ISRG and BDX?
Coloplast AS's Net Change in Cash of $59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Medical Devices & Instruments company?
A good Net Change in Cash depends on the Medical Devices & Instruments industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Coloplast AS and its competitors. Coloplast AS's current Net Change in Cash is $59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current Net Change in Cash is $59 Mil. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Net Change in Cash is $59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBY) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBY:

  • Net Change in Cash: $59 Mil
  • GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score

Get the complete analysis for CLPBY

Net Change in Cash is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.70
Price
$13.05
GF Value